Figure 5. FPR agonist Cmpd17b reduces cardiac inflammation and injury 48 h post I–R.

(a) Representative immunofluorescent images of LV neutrophil content (using anti-Ly-6B.2 antibody) from sham, vehicle- and FPR agonist-treated (Cmpd17b or Cmpd43, both 50 mg kg⁻¹ per day, i.p.) mice, 48 h post I–R (× 40 magnification, scale bars, 100 μm). (b) Pooled data for LV Ly-6B.2-positive immunofluorescence. (c) End point plasma Cmpd17b and Cmpd43 concentrations after 24 and 48 h reperfusion in mice in vivo. (d) Quantification of dead:viable cells from CardioTAC-stained LV sections 48 h post I–R (expressed as fold sham). Results are expressed as mean±s.e.m., with n (number of mice) per group indicated below the x axis. ^#P<0.05, ^###P<0.001 and ^####P<0.0001 versus sham and *P<0.05 versus vehicle-treated mice on one-way ANOVA with Dunnett's post hoc test. Shams (open symbols/bars); I–R (black symbols/bars); Cmpd17b (blue symbols/bars); Cmpd43 (red symbols/bars).